

Discussions with leaders: *JNM* contributor Ken Herrmann conducts a wide-ranging interview on leadership issues in nuclear and molecular imaging and therapy with Susanne Schaffert of Novartis Oncology. **Page 875**

CAR T-cell oncologic imaging: Krebs and colleagues provide an overview of cancer immunotherapy based on targeted approaches using chimeric antigen receptor T-cells, including cell tracking, clinical imaging, imaging models, novel constructs, and real-time applications. **Page 879**

Theranostics in G3 NENs: Waseem and colleagues review the current state of the art in somatostatin receptor theranostics for grade 3 neuroendocrine neoplasms, with special foci on histologic classification and choice of diagnostic imaging approach. **Page 882**

Cardiac sarcoidosis imaging: Ramirez and colleagues provide an educational overview of current theoretic and practical aspects of cardiac imaging, including PET and MRI, in evaluation of patients with suspected or established cardiac sarcoidosis. **Page 892**

Immuno-PET in mAb therapy: Reilly offers perspective on current clinical development pathways for monoclonal antibody therapies and previews an article in this issue of *JNM* on immuno-PET in patients with human epidermal growth factor receptor 3–positive tumors. **Page 899**

⁸⁹Zr-Anti-HER3 mAb immuno-PET: Menkevan der Houven van Oordt, McGeoch, and colleagues investigate biodistribution and uptake of ⁸⁹Zr-labeled GSK2849330, an anti-human epidermal growth factor receptor 3 monoclonal antibody, and evaluate target engagement as a function of antibody mass dose. **Page 902**

CTT1057 in PCa: Behr, Aggarwal, and colleagues detail a first-in-humans phase I study of CTT1057, an agent based on a phosphoramidate scaffold that irreversibly binds to prostate-specific membrane antigen, in patients with localized and metastatic prostate cancer. **Page 910**

MEK inhibitor–induced ¹³¹I uptake: ElMokh and colleagues target the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in *in vitro* studies and a murine model to induce radioiodine uptake for treatment of anaplastic thyroid carcinoma. **Page 917**

¹⁸F-DMFB for melanoma: Pyo and colleagues synthesize a novel ¹⁸F-labeled benzamide derivative with high melanin-targeting ability and evaluate its biologic characteristics in small animal models of malignant melanoma. **Page 924**

P2X7 radioligand PET probe: Fu, Lin, and colleagues evaluate the potential value of ¹⁸F-PTTP for targeting P2X7 receptors to differentiate inflammation from tumors, quantify peripheral inflammation, and screen new drugs. **Page 930**

¹⁷⁷Lu-DOTATATE in GEP NETs: Hope and colleagues provide practical guidance on treatment of patients with gastroenteropancreatic neuroendocrine tumors using somatostatin receptor–based peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE, based on recent consensus guidelines. **Page 937**

PET/CT and MRI in PCa detection: Chen, Zhang, Zhang, and colleagues explore the question of whether ⁶⁸Ga–prostate-specific membrane antigen PET/CT alone or in combination with multiparametric MR imaging can improve detection of clinically significant prostate cancer. **Page 944**

Androgen blockade and PSMA PET: Emmett and colleagues evaluate the effect of androgen blockade treatment on ⁶⁸Ga–prostate-specific membrane antigen–11 PET imaging in hormone-naïve and castrate-resistant men with metastatic prostate cancer. **Page 950**

¹⁷⁷Lu-PRLT in metastatic PCa: Barber, Singh, and colleagues assess clinical outcomes in ¹⁷⁷Lu–prostate-specific membrane antigen–targeted therapy in taxane chemotherapy–pretreated and –naïve patients with metastatic castration-resistant prostate cancer. **Page 955**

PSMA PET/CT vs. CT in PCa: Schmidt-Hegemann and colleagues report on a retrospective study determining the comparative effects of ⁶⁸Ga–prostate-specific membrane antigen PET/CT and standard CT-based imaging on radiotherapeutic approaches to prostate cancer. **Page 963**

PET in PCa LN metastases: Jilg and colleagues use ¹⁸F-choline and ⁶⁸Ga–prostate-specific membrane antigen PET/CT before lymphadenectomy in prostate cancer to determine relationships between lymph node metastatic rate and size of tumor deposits in metastases. **Page 971**

SVCA and ¹¹C-PBR28: Zanotti-Fregonara and colleagues test a supervised clustering algorithm in Alzheimer disease, mild cognitive impairment, and controls injected with the translocator protein ¹¹C-PBR28 and compare kinetic modeling results obtained with those from arterial input function. **Page 978**

Efflux enhancement by ABCB1: Tournier, Bauer, and colleagues perform PET with the weak P-glycoprotein substrate ¹¹C-metoclopramide in humans to elucidate the effect of ABCB1 function on its brain kinetics. **Page 985**

Brain BACE1 in NHPs: Takano and colleagues quantitatively evaluate regional brain distribution of ¹⁸F-PF-06684511 under baseline and blocking conditions, assess target occupancy of β-secretase 1 inhibitors in nonhuman primates, and use whole-body PET to estimate effective radiation doses. **Page 992**

PET/CT in bacteremia treatment: Berrevoets and colleagues investigate the safety of a shorter duration of treatment in patients with high-risk *Staphylococcus aureus* bacteremia without signs of metastatic infection, determined by ¹⁸F-FDG PET/CT and echocardiography. **Page 998**

Toward novel ¹⁸F-amino acids tracers: Nodwell and colleagues examine *in vitro* and *in vivo* studies the structure–activity relationships of a series of ¹⁸F-labeled amino acids predicted to be substrates of the large, neutral L-type amino acid transporter system. **Page 1003**

Improved minigastrin for theranostic use: Klingler and colleagues present a new minigastrin analog, DOTA-MGS5, with site-specific C terminus modifications showing a highly optimized targeting profile and promise in cholecystokinin-2 receptor–expressing malignancies. **Page 1010**

¹⁸F-AIF-PSMA-11 PET/CT: Lütje and colleagues compare the prostate-specific membrane antigen (PSMA)–targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of ¹⁸F-AIF, with those of ⁶⁸Ga-PSMA-11 in imaging PSMA-expressing xenografts. **Page 1017**

Visualization of KOR active state: Li and colleagues report on development and evaluation of ¹¹C-EKAP, compare it with ¹¹C-GR103545 in PET imaging of κ opioid receptors in nonhuman primates, and describe the new tracer’s potential in theranostic applications. **Page 1023**

Vision PET/CT system: Sluis and colleagues report on the performance of the Biograph Vision digital PET/CT system according to the NEMA NU 2-2012 standard for reliability, reproducibility, and intersystem comparability. **Page 1031**